# VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

> **NCT03690986** · PHASE1 · RECRUITING · sponsor: **Emory University** · enrollment: 50 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **BIOLOGICAL:** VX15/2503
- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03690986
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-11-01
- **Primary completion:** 2026-06-04
- **Final completion:** 2027-11-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03690986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03690986, "VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03690986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*